Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by
Health Canada in March 2007 and by the EMEA in September 2007. Among ACS patients,
fondaparinux is indicated for the treatment of UA/NSTEMI in patients for whom urgent PCI
(within 2 hours) is not indicated, and for the treatment of STEMI in patients who are managed
with thrombolytics or who are initially to receive no other form of reperfusion therapy. The
approved prescribing information for fondaparinux in ACS provides recommendations for use in
patients undergoing PCI. The purpose of this study is to evaluate physician adherence to this
prescribing information in ACS patients treated with fondaparinux and who undergo PCI. The
primary endpoint is the proportion of patients with ACS treated with fondaparinux, for whom
the prescribing information during PCI was followed (i.e., adjunctive anticoagulant therapy
administered at the time of PCI). Measurement of the effectiveness or safety of fondaparinux
use in ACS patients is not within the scope of this study.
ARIXTRA® is a trademark of the GlaxoSmithKline group of companies.